Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zelira Therapeutics ( (AU:ZLD) ) has shared an update.
Zelira Therapeutics has made significant progress in its HOPE® autism drug program, receiving positive feedback from the FDA for its Investigative New Drug (IND) application. This feedback has helped the company define its study’s target population and endpoints, advancing the development of treatments for irritability associated with ASD. Additionally, Zelira secured patents for its HOPE® 1 and HOPE® 2 formulations, strengthening its drug development initiatives. The company also received a US$1.4 million loan to support its clinical trials and working capital, which was later converted into a convertible note.
More about Zelira Therapeutics
Zelira Therapeutics Limited operates in the pharmaceutical industry, focusing on the development of cannabinoid-based medicines. The company is primarily engaged in creating treatments for conditions such as Autism Spectrum Disorder (ASD) and has a market focus on innovative drug formulations and clinical trials.
YTD Price Performance: -21.84%
Average Trading Volume: 469
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.53M
For a thorough assessment of ZLD stock, go to TipRanks’ Stock Analysis page.